|
시장보고서
상품코드
2140879
자궁 질환 치료제 시장 규모, 점유율 및 성장 분석 : 질환 유형별, 약제 클래스별, 투여 경로별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)Uterine Diseases Therapeutics Market Size, Share, and Growth Analysis, By Disease Type (Uterine Fibroids, Endometriosis), By Drug Class, By Route of Administration, By End User, By Region - Industry Forecast 2026-2033 |
||||||
세계의 자궁 질환 치료제 시장 규모는 2024년에 394억 달러로 평가되며, 2025년 406억 4,000만 달러에서 2033년까지 520억 4,000만 달러로 확대하며, 예측 기간(2026-2033년)에 CAGR 3.14%로 성장할 것으로 전망되고 있습니다.
전 세계 자궁 질환 치료제 시장에는 자궁근종, 자궁내막증, 자궁선근증 등의 질환에 대한 의약품 및 저침습 의료기기 등 폭넓은 치료 옵션이 포함되어 있습니다. 이 시장을 주도하는 요인은 주로 생식 연령 여성의 상당 부분에 영향을 미치는 이러한 질환의 유병률 증가와 이에 따른 의료비 상승입니다. 주목할 만한 동향으로는 자궁 보존 요법으로의 전환이 꼽히며, 이에 따라 회복 기간을 단축하는 혁신적인 경구 요법 및 표적 분자 치료제에 대한 수요가 증가하고 있습니다. 선택적 프로게스테론 수용체 조절제나 영상 유도 절제 장치와 같은 치료법에 대한 관심이 급속히 높아지는 가운데, 인도나 브라질과 같은 신흥 시장은 큰 수익 기회를 제공하고 있으며, 가까운 미래에 세계 시장 규모를 중요한 전환점으로 끌어올릴 것으로 전망됩니다.
세계 자궁 질환 치료제 시장의 성장 요인
자궁근종, 자궁내막증, 자궁선근증과 같은 자궁 질환의 유병률 증가로 인해 의료진은 효과적인 치료법을 모색해야 하는 상황에 놓여 있으며, 그 결과 자궁 질환 치료제의 대상 환자층이 확대되고 있습니다. 이러한 질환에 대한 의식의 향상와 진단 기술의 발전으로 인해 더 많은 여성이 조기에 진단을 받게 되었으며, 필요한 치료를 통한 적시 개입이 촉진되고 있습니다. 그 결과, 제약 기업은 기존 의약품과 혁신적인 의약품 모두에 대한 수요 증가에 직면하고 있으며, 이에 따라 연구개발 투자가 증가하고 다양한 지역에서의 사업 확장이 진행되고 있습니다. 이러한 상황은 학술기관과 업계 관계자 간의 협력을 촉진하고, 획기적인 치료법의 임상 현장 도입을 가속화하고 있습니다.
세계 자궁 질환 치료제 시장의 제약 요인
전 세계 자궁 질환 치료제 시장은 주로 혁신적인 생물제제 및 표적 치료에 수반되는 높은 비용으로 인해 몇 가지 중대한 제약에 직면해 있습니다. 이러한 고가 책정은 특히 보험 급여 옵션이 제한된 지역에서 의료 시스템에 재정적 부담을 가중시키고 있습니다. 그 결과, 보험사는 급여 승인을 하기 전에 철저한 약제경제학적 평가를 요구하고 있으며, 이는 시장으로의 적시 진입을 방해하고 환자가 이러한 첨단 치료를 받을 기회를 제한할 가능성이 있습니다. 그 결과, 의료 제공자들은 보다 전통적이고 비용 대비 효과가 높은 치료 옵션을 우선시하는 경향이 있으며, 비록 임상적 우월성이 입증되었더라도 신약의 보급이 정체될 우려가 있습니다. 또한 환자의 본인 부담금이 높아지면 치료 순응도가 떨어지게 되어, 고가 치료제의 상용화에 대한 과제를 더욱 심각하게 만드는 요인이 됩니다.
세계 자궁 질환 치료제 시장의 동향
전 세계 자궁 질환 치료제 시장에서는 임상 현장에서의 유전체 프로파일링 도입 확대에 힘입어 정밀 의학(Precision Medicine)으로의 큰 전환이 진행되고 있습니다. 이러한 동향에 따라 의료 제공자는 자궁 질환의 분자 아형을 특정할 수 있게 되어, 기존의 화학요법에 대한 의존도를 낮추면서 더 표적화된 효과적인 치료법을 제공할 수 있게 됩니다. 시퀀싱 기술의 비용이 지속적으로 하락하는 가운데, 의료제도에서는 정밀 의학 프로토콜 도입에 대한 인센티브가 점점 더 높아지고 있습니다. 이러한 진화를 통해 학술기관, 진단 기업, 제약 개발 기업 간의 견고한 협력이 촉진되고 있으며, 자궁육종이나 자궁내막암 등의 질환에 대한 돌연변이 특이적 치료법과 동반 진단제의 공동 개발을 목표로 하고 있습니다.
자주 묻는 질문
목차
서론
조사 방법
개요
시장 역학과 전망
주요 시장 인사이트
세계의 자궁 질환 치료제 시장 규모 : 질환 유형별
세계의 자궁 질환 치료제 시장 규모 : 약제 클래스별
세계의 자궁 질환 치료제 시장 규모 : 투여 경로별
세계의 자궁 질환 치료제 시장 규모 : 최종사용자별
세계의 자궁 질환 치료제 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
KSA 26.10.14Global Uterine Diseases Therapeutics Market size was valued at USD 39.4 Billion in 2024 and is poised to grow from USD 40.64 Billion in 2025 to USD 52.04 Billion by 2033, growing at a CAGR of 3.14% during the forecast period (2026-2033).
The global uterine diseases therapeutics market encompasses a range of treatment options, including medications and minimally invasive devices for conditions like fibroids, endometriosis, and adenomyosis. The market is primarily driven by the increasing prevalence of these disorders, affecting a significant portion of women of reproductive age, alongside the rising healthcare costs associated with them. A notable trend is the shift towards uterus-preserving treatments, highlighting the demand for innovative oral therapies and targeted molecular drugs that reduce recovery times. With a burgeoning interest in therapies like selective progesterone-receptor modulators and image-guided ablation devices, emerging markets such as India and Brazil present substantial revenue opportunities, propelling the global market value toward significant milestones in the approaching future.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Uterine Diseases Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Uterine Diseases Therapeutics Market Segments Analysis
Global uterine diseases therapeutics market is segmented by disease type, drug class, route of administration, end user and region. Based on disease type, the market is segmented into Uterine Fibroids, Endometriosis, Uterine Cancer, Adenomyosis and Others. Based on drug class, the market is segmented into Gonadotropin Releasing Hormone Agonists Antagonists, Hormonal Contraceptives, NSAIDs Pain Modifiers, Chemotherapeutic Agents and Others. Based on route of administration, the market is segmented into Oral, Parenteral Injectable and Intrauterine Systems. Based on end user, the market is segmented into Hospitals Cardiac Centers Clinics, Ambulatory Surgical Centers and Specialty Gynecology Centers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Uterine Diseases Therapeutics Market
The increasing prevalence of uterine conditions like fibroids, endometriosis, and adenomyosis is driving healthcare providers to explore effective treatment options, thereby broadening the patient population for uterine disease therapeutics. Enhanced awareness of these diseases and advancements in diagnostic techniques ensure that a greater number of women are diagnosed earlier, promoting timely intervention with necessary therapies. As a result, pharmaceutical companies face an uptick in demand for both established and innovative drug solutions, leading to increased investment in research and development and expansion efforts across various regions. This scenario fosters collaborations between academic institutions and industry players, expediting the introduction of groundbreaking therapies into clinical practice.
Restraints in the Global Uterine Diseases Therapeutics Market
The Global Uterine Diseases Therapeutics market faces several significant restraints, primarily driven by the high costs associated with innovative biologics and targeted therapies. These premium price points exert financial strain on healthcare systems, especially in areas with limited reimbursement options. Consequently, payers demand thorough pharmacoeconomic evaluations prior to granting coverage, which can hinder timely market access and restrict patient availability to these advanced treatments. As a result, healthcare providers may favor more traditional and cost-effective treatment options, stalling the uptake of novel therapeutics even when they demonstrate clinical advantages. Furthermore, elevated out-of-pocket costs for patients can contribute to treatment non-adherence, further entrenching the challenges in commercializing expensive therapeutic products.
Market Trends of the Global Uterine Diseases Therapeutics Market
The Global Uterine Diseases Therapeutics market is experiencing a significant shift towards precision medicine, driven by the growing adoption of genomic profiling in clinical settings. This trend enables healthcare providers to identify molecular subtypes of uterine pathologies, facilitating more targeted and effective treatment options while reducing the reliance on traditional chemotherapy. As the costs of sequencing technology continue to decline, healthcare systems are increasingly incentivized to implement precision protocols. This evolution is fostering robust collaborations between academic institutions, diagnostic companies, and pharmaceutical developers, aimed at co-developing mutation-specific therapies and companion diagnostics for conditions such as uterine sarcoma and endometrial carcinoma.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Uterine Diseases Therapeutics Market Size by Disease Type & CAGR (2026-2033)
- Market Overview
- Uterine Fibroids
- Endometriosis
- Uterine Cancer
- Adenomyosis
- Others
Global Uterine Diseases Therapeutics Market Size by Drug Class & CAGR (2026-2033)
- Market Overview
- Gonadotropin Releasing Hormone Agonists Antagonists
- Hormonal Contraceptives
- NSAIDs Pain Modifiers
- Chemotherapeutic Agents
- Others
Global Uterine Diseases Therapeutics Market Size by Route of Administration & CAGR (2026-2033)
- Market Overview
- Oral
- Parenteral Injectable
- Intrauterine Systems
Global Uterine Diseases Therapeutics Market Size by End User & CAGR (2026-2033)
- Market Overview
- Hospitals Cardiac Centers Clinics
- Ambulatory Surgical Centers
- Specialty Gynecology Centers
Global Uterine Diseases Therapeutics Market Size & CAGR (2026-2033)
- North America (Disease Type, Drug Class, Route of Administration, End User)
- US
- Canada
- Europe (Disease Type, Drug Class, Route of Administration, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Disease Type, Drug Class, Route of Administration, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Disease Type, Drug Class, Route of Administration, End User)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Disease Type, Drug Class, Route of Administration, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- AbbVie Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Myovant Sciences Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sumitomo Pharma Co Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bayer AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AstraZeneca plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- F Hoffmann-La Roche Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Genentech Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GlaxoSmithKline plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bristol Myers Squibb Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Takeda Pharmaceutical Company Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Johnson & Johnson Services Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi SA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Teva Pharmaceutical Industries Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Viatris Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sandoz International GmbH
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Organon & Co
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
